PORTLAND, GA, UNITED STATES, November 5, 2024 /EINPresswire / -- The global Implantable Insulin Pump Market was pegged at $2.67 billion in 2020, and is estimated to reach $6.44 billion by 2030, ...

as well as specialty pumps such as insulin, patient-controlled analgesia, enteral, and implantable infusion pumps. The report focuses on application areas such as diabetes management, pain ...

The 39 year-old star of TV, film and stage has battled with the potentially fatal condition since his early 20s, but has ...

As pharmaceutical companies strive to expand access to medications in emerging markets, low-cost, easy-to-use drug delivery ...

The Cardiovascular Portfolio segment offers implantable cardiac pacemakers ... The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and ...

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

Insulet raised its annual revenue growth forecast on Thursday, banking on strong demand for its wearable insulin pumps.

Tandem Diabetes Care (TNDM) and Insulet (PODD) stocks draw outperform ratings at Bernstein as insulin pump makers prepare for ...

Insulin pump therapy, also known as continuous subcutaneous insulin infusion (CSII), is an important and evolving form of insulin delivery, which is mainly used for people with type 1 diabetes.

Bernstein initiated coverage of Insulet (PODD) with an Outperform rating and $300 price target Innovation is driving accelerated insulin pump ...